10. Charcot-Marie-Tooth disease
31 clinical trials, 38 drugs (DrugBank: 9 drugs), 11 drug target genes, 14 drug target pathways
Searched query = "Charcot-Marie-Tooth disease", "CMT"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCTs031190109 | 03/10/2019 | 03/10/2019 | Ascorbic acid treatment for childhood Charcot-Marie-Tooth disease 1A | Ascorbic acid treatment for childhood Charcot-Marie-Tooth disease 1A - Ascorbic acid for CMT1A | Charcot-Marie-Tooth disease type 1A CMT1A;G600 | ascorbic acid dayly intake | FUJII KATSUNORI | NULL | Recruiting | Not applicable | < 18age old | Both | 12 | Phase 2 | Japan |
| 2 | JPRN-UMIN000036332 | 2019/06/15 | 28/03/2019 | Ascorbic acid treatment for Charcot-Marie-Tooth disease type 1A | Ascorbic acid treatment for Charcot-Marie-Tooth disease type 1A - Ascorbic acid treatment for CMT1A | Charcot-Marie-Tooth diease type 1A | Ascorbic acid treatment: 20mg/kg/day, dayly | Chiba University | NULL | Pending | 1years-old | Not applicable | Male and Female | 10 | Phase 1 | Japan |
| 3 | NCT00484510 (ClinicalTrials.gov) | April 2007 | 8/6/2007 | High Dose Ascorbic Acid Treatment of CMT1A | A Randomized, Placebo-controlled, Double Masked 120 Subject Futility Design Clinical Trial of Ascorbic Acid Treatment of Charcot Marie Tooth Disease Type 1A. | Charcot-Marie-Tooth Disease, Type Ia | Drug: Ascorbic acid (Vitamin C);Drug: placebo | Wayne State University | Muscular Dystrophy Association;Charcot-Marie-Tooth Association | Completed | 13 Years | 70 Years | Both | 110 | Phase 2;Phase 3 | United States |
| 4 | NCT00271635 (ClinicalTrials.gov) | January 2006 | 3/1/2006 | Ascorbic Acid Treatment in CMT1A Trial (AATIC) | Phase 2 Study of Ascorbic Acid Treatment in Charcot-Marie-Tooth Type 1A | Charcot-Marie-Tooth Disease;Hereditary Motor and Sensory Neuropathies | Drug: Placebo;Drug: ascorbic acid | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | NULL | Completed | 12 Years | 25 Years | Both | 13 | Phase 2 | Netherlands |
| 5 | EUCTR2006-000032-27-IT (EUCTR) | 19/10/2005 | 14/03/2006 | MULTICENTRE RANDOMISED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF LONG-TERM ASCORBIC ACID TREATMENT IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A CMT-TRIAAL CMT-TRial Italian with Ascorbic Acid Long term - CMT-TRIAAL | MULTICENTRE RANDOMISED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF LONG-TERM ASCORBIC ACID TREATMENT IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A CMT-TRIAAL CMT-TRial Italian with Ascorbic Acid Long term - CMT-TRIAAL | Charcot-Marie-Tooth disease type 1A CMT1A MedDRA version: 6.1;Level: HLGT;Classification code 10034606 | Trade Name: CEBION 500MG 20CPR MAST.ARAN INN or Proposed INN: ACIDO ASCORBICO DC.IT INN or Proposed INN: SODIO ASCORBATO DC.IT | ISTITUTO NEUROLOGICO CARLO BESTA | NULL | Not Recruiting | Female: yes Male: yes | 202 | Italy | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | JPRN-UMIN000001535 | 2005/04/01 | 01/01/2009 | A multicenter, randomized open trial of ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A | Charcot-Marie-Tooth disease 1A | Ascorbic acid (AA) treatment group (12 weeks oral AA (20mg/kg/day) no AA treatment group | New treatment strategies for intractable neuropathies based on its pathomechanism.The Research Grant 19A-5 for Nervous and Mental Disorders from the Ministry of Health, Labour and Welfare. | NULL | Complete: follow-up complete | 15years-old | 75years-old | Male and Female | 60 | Phase 1;Phase 2 | Japan | |
| 7 | EUCTR2004-004501-24-IT (EUCTR) | 22/12/2004 | 13/02/2007 | Multicentre, randomised, double blind, placebo controlled trial of ascorbic acid treatment in Charcot-Marie-Tooth Disease Type 1A CMT1A . | Multicentre, randomised, double blind, placebo controlled trial of ascorbic acid treatment in Charcot-Marie-Tooth Disease Type 1A CMT1A . | Charcot-Marie-Tooth Disease Type 1A CMT1A . MedDRA version: 6.1;Level: HLT;Classification code 10022031 | Trade Name: CEBION 500*20CPR MAST 500MG Product Name: ACIDO ASCORBICO INN or Proposed INN: Ascorbic acid vit C | ISTITUTO NEUROLOGICO CARLO BESTA | NULL | Not Recruiting | Female: yes Male: yes | 200 | Italy |